BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Li F, Zheng T, Gu X. Prognostic risk factor analysis and nomogram construction for primary liver cancer in elderly patients based on SEER database. BMJ Open 2022;12:e051946. [PMID: 36288830 DOI: 10.1136/bmjopen-2021-051946] [Reference Citation Analysis]
2 Goodwin B, Lou J, Butchy M, Wilson T, Atabek U, Spitz F, Hong Y. Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices. The American Surgeon. [DOI: 10.1177/00031348221124323] [Reference Citation Analysis]
3 Wang W, Li J, Liang B, Lv X, Zhu R, Wang J, Huang Z, Yang S, Zhang E. Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma: A propensity score matched study. Front Oncol 2022;12:980736. [DOI: 10.3389/fonc.2022.980736] [Reference Citation Analysis]
4 Zhou Y, Yin S, Zhao L, Zhang X, Li M, Ding J, Yan K, Jing X. CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma. Front Oncol 2022;12:897090. [PMID: 35651804 DOI: 10.3389/fonc.2022.897090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim SH, Navot B, Guniganti P, Gavlin A, Hecht EM, Kierans AS. Liver Transplant for Non-Hepatocellular Malignancies: A Review for Radiologists. AJR Am J Roentgenol 2022. [PMID: 35544376 DOI: 10.2214/AJR.22.27783] [Reference Citation Analysis]
6 Xu J, Li S, Feng Y, Zhang J, Peng Y, Wang X, Wang H. The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery. CMAR 2022;Volume 14:1795-806. [DOI: 10.2147/cmar.s361462] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Chen X, Sun S, Lu Y, Shi X, Wang Z, Chen X, Han G, Zhao J, Gao Y, Wang X. Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis. Ann Transl Med 2022;10:434. [PMID: 35571416 DOI: 10.21037/atm-21-5391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ahn H, Ryu J, Lee J, Mun SJ, Hong Y, Shin Y, Chung K, Son MJ. Generation of An Induced Pluripotent Stem Cell Line from Human Liver Fibroblasts from A Patient with Combined Hepatocellular-Cholangiocarcinoma. Cell J 2022;24:133-9. [PMID: 35451583 DOI: 10.22074/cellj.2022.7765] [Reference Citation Analysis]
9 Zhou YW, Li QF, Chen YY, Wang K, Pu D, Chen XR, Li CH, Jiang L, Wang Y, Li Q, Yang Y, Gou HF, Bi F, Liu JY, Chen Y, Qiu M. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study. Eur J Surg Oncol 2022:S0748-7983(22)00065-8. [PMID: 35115213 DOI: 10.1016/j.ejso.2022.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rastogi A, Patil N, Sahai P, Sharma N, Shasthry S, Mukund A, Laroia S, Kumar G, Pamecha V, Sarin S. Combined hepatocellular cholangiocarcinoma in hepatectomy specimens: A clinicopathologic analysis. Indian J Pathol Microbiol 2022;0:0. [DOI: 10.4103/ijpm.ijpm_357_22] [Reference Citation Analysis]
11 Chen X, Lu Y, Shi X, Chen X, Rong D, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma. J Oncol 2021;2021:3002480. [PMID: 34925507 DOI: 10.1155/2021/3002480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang Y, Zhou CW, Zhu GQ, Li N, Qian XL, Chong HH, Yang C, Zeng MS. A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma. Ann Transl Med 2021;9:1518. [PMID: 34790724 DOI: 10.21037/atm-21-2500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
14 Choi SH, Jeon SK, Lee SS, Lee JM, Hur BY, Kang HJ, Kim H, Park Y. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol 2021. [PMID: 34037829 DOI: 10.1007/s00330-021-07984-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Zhang F, Hu KS, Lu SX, Li M, Chen RX, Ren ZG, Shi YH, Yin X. Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma. Cancer Biomark 2021;31:211-25. [PMID: 33896819 DOI: 10.3233/CBM-200643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kim EJ, Yoo C, Kang HJ, Kim KP, Ryu MH, Park SR, Lee D, Choi J, Shim JH, Kim KM, Lim YS, Lee HC, Ryoo BY. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int 2021;41:1398-408. [PMID: 33548073 DOI: 10.1111/liv.14813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
18 Kawasaki H, Akazawa Y, Razumilava N. Progress toward improving outcomes in patients with cholangiocarcinoma. Curr Treat Options Gastroenterol 2021;19:153-68. [PMID: 33883870 DOI: 10.1007/s11938-021-00333-2] [Reference Citation Analysis]
19 Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Int J Med Sci 2021;18:187-98. [PMID: 33390787 DOI: 10.7150/ijms.50883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
20 Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep 2020;19:478-85. [PMID: 33415066 DOI: 10.1007/s11901-020-00556-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Meloni MF, Francica G, Chiang J, Coltorti A, Danzi R, Laeseke PF. Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. J Ultrasound Med 2021;40:879-94. [PMID: 32936485 DOI: 10.1002/jum.15471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]